| abstract |
The present invention relates generally to the field of therapeutic compounds, and more particularly to 4-(5-(4,7-dimethylbenzofuran-2-yl)-1,2,4-oxadiazol-3-yl ) crystalline form of benzoic acid (referred to herein as "BHBA-001"), which compound is in particular a (selective) retinoic acid receptor beta (RARβ) (eg RARβ2) agonist. The invention also relates to pharmaceutical compositions comprising such crystalline forms, and such crystalline forms and compositions (selectively) activate RARβ (eg, RARβ2) in vitro and in vivo to cause or promote neurite development, neurite outgrowth and Use of neurite regeneration, and the use of such crystalline forms and compositions in the treatment of diseases and conditions mediated by RARβ (eg RARβ2), diseases and conditions ameliorated by activation of RARβ (eg RARβ2), and the like, including, for example, the nervous system Use in injuries such as spinal cord injury. |